Takeda Pharmaceutical Company’s Turnstone Biologics TSBX Stock Holding History

Takeda Pharmaceutical Company’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-895,824	Closed	-$322K	–	11
2025 Q2	$322K	Hold	895,824	–	–	1.64%	8
2025 Q1	$367K	Hold	895,824	–	–	2.27%	8
2024 Q4	$448K	Hold	895,824	–	–	1.69%	8
2024 Q3	$499K	Hold	895,824	–	–	1.31%	8
2024 Q2	$2.35M	Hold	895,824	–	–	1.01%	6
2024 Q1	$2.35M	Hold	895,824	–	–	0.81%	8
2023 Q4	$2.28M	Buy	+895,824	New	+$2.34M	0.7%	8

Takeda Pharmaceutical Company's TSBX Position: Q3 2025 in Review

Takeda Pharmaceutical Company sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 895,824 shares — an estimated $322K sold.

Takeda Pharmaceutical Company first reported a position in TSBX in Q4 2023 and held it in 7 quarters. The position peaked at $2.35M in Q2 2024. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

Takeda Pharmaceutical Company reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
Takeda Pharmaceutical Company sold 895,824 Turnstone Biologics shares in Q3 2025, an estimated $322K.
Takeda Pharmaceutical Company first reported a position in Turnstone Biologics in Q4 2023 and held it in 7 quarters.
Takeda Pharmaceutical Company's Turnstone Biologics position peaked at $2.35M in Q2 2024.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.